Erlotinib in African Americans with advanced non-small cell lung cancer: A prospective randomized study with genetic and pharmacokinetic analyses

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 2, 2014, Pages 182-191

  Phelps, M A ^a,b   Stinchcombe, T E ^c   Blachly, J S ^b   Zhao, W ^b   Schaaf, L J ^a,b   Starrett, S L ^d   Wei, L ^a   Poi, M ^b   Wang, D ^b   Papp, A ^b   Aimiuwu, J ^a   Gao, Y ^a   Li, J ^a   Otterson, G A ^b   Hicks, W J ^b   Socinski, M A ^c   Villalona Calero, M A ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; OSI 420; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGED; ALK GENE; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER CONTROL; CANCER GENETICS; CORRELATION ANALYSIS; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERANCE; EML4 GENE; ERYTHEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE TRANSLOCATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERPIGMENTATION; INTERSTITIAL PNEUMONIA; INTESTINE OBSTRUCTION; KRAS GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA HALF LIFE; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; STOMACH ULCER; SURVIVAL TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TIME TO PROGRESSION; TREATMENT OUTCOME; XERODERMA; XEROSTOMIA;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHARMACOGENETICS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84904855517     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.93     Document Type: Article

References (52)

1. SEER Cancer Statistics Review, 1975-2000. (eds. Lag, R., M.P., E., C.L., K. et al.) (National Cancer Institute, Bethesda, MD, 2003
2. Gadgeel, S.M., Severson, R.K., Kau, Y., Graff, J., Weiss, L.K. & Kalemkerian, G.P. Impact of race in lung cancer: Analysis of temporal trends from a surveillance, epidemiology, and end results database. Chest 120, 55-63 (2001 (Pubitemid 32744857)
3. Ward, E. et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J. Clin. 54, 78-93 (2004 (Pubitemid 38519418)
4. Hunt, J.D. et al. Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. Cancer Epidemiol. Biomarkers Prev. 11, 1405-1412 (2002 (Pubitemid 35340377)
5. Wu, X. et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J. Natl. Cancer Inst. 94, 681-690 (2002 (Pubitemid 34552489)
6. Bach, P.B., Cramer, L.D., Warren, J.L. & Begg, C.B. Racial differences in the treatment of early-stage lung cancer. N. Engl. J. Med. 341, 1198-1205 (1999 (Pubitemid 29480659)
7. Blackstock, A.W. et al. Outcomes among African-American/non-African- American patients with advanced non-small-cell lung carcinoma: Report from the Cancer and Leukemia Group B. J. Natl. Cancer Inst. 94, 284-290 (2002 (Pubitemid 34196322)
8. Felip, E. & Rosell, R. Clinical experience with erlotinib in non-small-cell lung cancer. Drugs Today (Barc). 42, 147-156 (2006
9. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004 (Pubitemid 38637993)
10. Maemondo, M. et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010
11. Paez, J.G. et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004 (Pubitemid 38720929)
12. Jänne, P.A. et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J. Clin. Oncol. 30, 2063-2069 (2012
13. Rudin, C.M. et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol. 26, 1119-1127 (2008
14. Heist, R.S. & Christiani, D. EGFR-Targeted therapies in lung cancer: Predictors of response and toxicity. Pharmacogenomics 10, 59-68 (2009
15. Perez-Soler, R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin. Lung Cancer 6 (suppl. 1), S20-S23 (2004
16. Li, J., Zhao, M., He, P., Hidalgo, M. & Baker, S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res. 13, 3731-3737 (2007 (Pubitemid 46955138)
17. Rakhit, A. et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: Computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur. J. Clin. Pharmacol. 64, 31-41 (2008
18. Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001 (Pubitemid 32268418)
19. He, P., Court, M.H., Greenblatt, D.J. & Von Moltke, L.L. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin. Pharmacol. Ther. 77, 373-387 (2005 (Pubitemid 40719266)
20. Information NCfB. DbSNP Short Genetic Variations (edited 26 June 2012) (2012
21. Rotunno, M. et al. Phase I metabolic genes and risk of lung cancer: Multiple polymorphisms and mRNA expression. PLoS One 4, e5652 (2009
22. Wright, C.M. et al. Genetic association study of CYP1A1 polymorphisms identifies risk haplotypes in nonsmall cell lung cancer. Eur. Respir. J. 35, 152-159 (2010
23. Shi, Z. et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 67, 11012-11020 (2007 (Pubitemid 350145931)
24. Li, J., Cusatis, G., Brahmer, J., et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther. 6: 432-438 (2007 (Pubitemid 47328313)
25. Elens, L., Becker, M.L., Haufroid, V., et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics 21: 861-866 (2011
26. Elens, L. et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57, 1574-1583 (2011
27. Elens, L. et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12, 1383-1396 (2011
28. Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E. & Sadee, W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11, 274-286 (2011
29. White-Koning, M. et al. Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children. Clin. Cancer Res. 17, 4862-4871 (2011
30. Kraut, E.H. et al. Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Cancer Chemother. Pharmacol. 67, 579-586 (2011
31. Y un, C.H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. USA 105, 2070-2075 (2008
32. Roberts, P.J., Stinchcombe, T.E., Der, C.J. & Socinski, M.A. Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-Targeted therapy? J. Clin. Oncol. 28, 4769-4777 (2010
33. Mok, T. et al. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 5, 1609-1615 (2010
34. Scheffler, M., Di Gion, P., Doroshyenko, O., Wolf, J. & Fuhr, U. Clinical pharmacokinetics of tyrosine kinase inhibitors: Focus on 4-Anilinoquinazolines. Clin. Pharmacokinet. 50, 371-403 (2011
35. Lu, J.F. et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin. Pharmacol. Ther. 80, 136-145 (2006
36. Thomas, F. et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur. J. Cancer 45, 2316-2323 (2009
37. Nallani, S.C., Genter, M.B. & Desai, P.B. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: Comparative evaluation with paclitaxel. Cancer Chemother. Pharmacol. 48, 115-122 (2001 (Pubitemid 32710222)
38. Fujitaka, K., Oguri, T., Isobe, T., Fujiwara, Y. & Kohno, N. Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer. Cancer Chemother. Pharmacol. 48, 42-46 (2001 (Pubitemid 32662435)
39. Waller, L.L., Miller, A.A. & Petty, W.J. Using erlotinib to treat patients with nonsmall cell lung cancer who continue to smoke. Lung Cancer 67, 12-16 (2010
40. Hughes, A.N. et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J. Clin. Oncol. 27, 1220-1226 (2009
41. Shepherd, F.A. et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005 (Pubitemid 41058344)
42. Y oshioka, H. et al.; Okayama Lung Cancer Study Group. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J. Thorac. Oncol. 5, 99-104 (2010
43. D'Angelo, S.P. et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J. Clin. Oncol. 29, 2066-2070 (2011
44. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010
45. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000
46. Dai, Z., Papp, A.C., Wang, D., Hampel, H. & Sadee, W. Genotyping panel for assessing response to cancer chemotherapy. BMC Med. Genomics 1, 24 (2008
47. Wang, D., Johnson, A.D., Papp, A.C., Kroetz, D.L. & Sadée, W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435CT affects mRNA stability. Pharmacogenet. Genomics 15, 693-704 (2005 (Pubitemid 41345321)
48. Hume, R. Prediction of lean body mass from height and weight. J. Clin. Pathol. 19, 389-391 (1966
49. Mitsudomi, T. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513-2520 (2005 (Pubitemid 47050841)
50. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 448, 561-566 (2007 (Pubitemid 47206930)
51. Koivunen, J.P. et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 14, 4275-4283 (2008
52. Team RDC. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, 2008.